Results 1 to 10 of about 1,958,009 (180)

Desmopressin in moderate hemophilia A patients: a treatment worth considering [PDF]

Haematologica, 2018
Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed.
Janneke I. Loomans, Marieke J.H.A. Kruip, Manuel Carcao, Shannon Jackson, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Helen Platokouki, Erik Beckers, Jan Voorberg, Johanna G. van der Bom, Karin Fijnvandraat, for the RISE consortium   +12 more
doaj   +6 more sources

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen–Bethesda assay, potentially leading to false-positive results for FVIII inhibitors.
Rick Timmerije, Saskia E.M. Schols, Daniëlle Meijer, Wideke Barteling, An K. Stroobants, Sanna R. Rijpma   +5 more
doaj   +2 more sources

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Hemophilia A (HA) is an X-linked disorder due to deleterious variants in the factor VIII (FVIII) gene (F8). Few studies from large cohorts have explored F8 genotype in people with HA with origins other than North American and European ...
Luciana Werneck Zuccherato, Renan Pedra Souza, Ricardo Mesquita Camelo, Márcio Antônio Portugal Santana, Maíse Moreira Dias, Letícia Lemos Jardim, Andrea Gonçalves de Oliveira, Claudia Santos Lorenzato, Monica Hermida Cerqueira, Vivian Karla Brognoli Franco, Rosangela de Albuquerque Ribeiro, Leina Yukari Etto, Maria do Rosario Ferraz Roberti, Fábia Michelle Rodrigues de Araújo Callado, Maria Aline Ferreira de Cerqueira, Ieda Solange de Souza Pinto, Andrea Aparecida Garcia, Tania Hissa Anegawa, Daniele Campos Fontes Neves, Daniel Gonçalves Chaves, Suely Meireles Rezende   +20 more
doaj   +2 more sources

Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies

Medicina, 2023
Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a sudden and unexpected bleeding episode in a patient with no personal or family history of bleeding diathesis, and with a typical laboratory feature, i.e., a ...
Renato Marino
doaj   +1 more source

Purified factor VIII [PDF]

BMJ, 1995
Patients with haemophilia A lack only factor VIII. Why give them anything else as replacement treatment? Previously the answer to this question was determined largely by the practical difficulty in separating factor VIII from fibrinogen, fibronectin, and immunoglobulins, so that concentrates contained 2000 U/mg respectively, but concentrates prepared ...
E G, Tuddenham, M, Laffan
openaire   +2 more sources

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Research and Practice in Thrombosis and Haemostasis, 2022
Background Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti ...
Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L. Meeks, Jean‐Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L. Turecek, Nikola Tripkovic, Yesim Dargaud   +9 more
doaj   +1 more source

Prolonged elevations in haemostatic and rheological responses following psychological stress in low socioeconomic status men and women [PDF]

, 2003
Low socioeconomic status (SES) and psychological stress are associated with increased risk of coronary heart disease, and both may influence haemostatic responses.
Kunz-Ebrecht, S., Lowe, G.D.O., Rumley, A., Steptoe, A.   +3 more
core   +1 more source

Large-scale purification of factor VIII by affinity chromatography: optimization of process parameters [PDF]

, 1990
The optimization of a new process for the extraction of human coagulation factor VIII (FVIII) from plasma with the tailor-made affinity matrix dimethylaminopropylcarbamylpentyl-Sepharose CL-4B (C3---C5 matrix) is described.
Bantjes, Adriaan, Beugeling, Tom, Booy, Marcel P.W.M. te, Faber, Anita, Jonge, Egge de, König, Boudewijn W., Over, Jan, Riethorst, Waander, Wolterink, Ernst P.   +8 more
core   +6 more sources

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy

Frontiers in Immunology, 2020
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein.
Alex C. Chen, Xiaohe Cai, Chong Li, Liliane Khoryati, Marc A. Gavin, Carol H. Miao   +5 more
doaj   +1 more source

Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]

, 2000
Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N., Geiersberger, U., Gesierich, Wolfgang, Hartenstein, R., Munker, Reinhold, Pohlmann, H.   +5 more
core   +1 more source